Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30932365)

  • 1. Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment.
    Antoun S; Morel H; Souquet PJ; Surmont V; Planchard D; Bonnetain F; Foucher P; Egenod T; Krakowski I; Gaudin H; Debieuvre D
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):782-793. PubMed ID: 30932365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors which modulate the rates of skeletal muscle mass loss in non-small cell lung cancer patients: a pilot study.
    Atlan P; Bayar MA; Lanoy E; Besse B; Planchard D; Ramon J; Raynard B; Antoun S
    Support Care Cancer; 2017 Nov; 25(11):3365-3373. PubMed ID: 28593463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
    Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
    Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What's next in using CT scans to better understand cachexia?
    Antoun S; Rossoni C; Lanoy E
    Curr Opin Support Palliat Care; 2018 Dec; 12(4):427-433. PubMed ID: 30239385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
    Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
    Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT).
    Recio-Boiles A; Galeas JN; Goldwasser B; Sanchez K; Man LMW; Gentzler RD; Gildersleeve J; Hollen PJ; Gralla RJ
    Support Care Cancer; 2018 Jul; 26(7):2353-2359. PubMed ID: 29417293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscle mass and association to quality of life in non-small cell lung cancer patients.
    Bye A; Sjøblom B; Wentzel-Larsen T; Grønberg BH; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Jordhøy M
    J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):759-767. PubMed ID: 28493418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss.
    Gelhorn HL; Gries KS; Speck RM; Duus EM; Bourne RK; Aggarwal D; Cella D
    Qual Life Res; 2019 Jun; 28(6):1641-1653. PubMed ID: 30796591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study.
    Takayama K; Atagi S; Imamura F; Tanaka H; Minato K; Harada T; Katakami N; Yokoyama T; Yoshimori K; Takiguchi Y; Hataji O; Takeda Y; Aoe K; Kim YH; Yokota S; Tabeta H; Tomii K; Ohashi Y; Eguchi K; Watanabe K
    Support Care Cancer; 2016 Aug; 24(8):3473-80. PubMed ID: 27003901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
    Op den Kamp CM; Langen RC; Minnaard R; Kelders MC; Snepvangers FJ; Hesselink MK; Dingemans AC; Schols AM
    Lung Cancer; 2012 Apr; 76(1):112-7. PubMed ID: 22018880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of sarcopenia in patients undergoing complete resection for early non-small cell lung cancer.
    Suzuki Y; Okamoto T; Fujishita T; Katsura M; Akamine T; Takamori S; Morodomi Y; Tagawa T; Shoji F; Maehara Y
    Lung Cancer; 2016 Nov; 101():92-97. PubMed ID: 27794415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcopenic obesity by the ESPEN/EASO criteria for predicting mortality in advanced non-small cell lung cancer.
    Zhou J; Luo L; Xie L; Hu S; Tan L; Lei X; Luo X; Yang M
    Clin Nutr; 2023 Jun; 42(6):817-824. PubMed ID: 37084468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer.
    Kakinuma K; Tsuruoka H; Morikawa K; Furuya N; Inoue T; Miyazawa T; Mineshita M
    Thorac Cancer; 2018 Jan; 9(1):99-104. PubMed ID: 29067769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer.
    LeBlanc TW; Nipp RD; Rushing CN; Samsa GP; Locke SC; Kamal AH; Cella DF; Abernethy AP
    J Pain Symptom Manage; 2015 Apr; 49(4):680-9. PubMed ID: 25461669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS).
    LeBlanc TW; Samsa GP; Wolf SP; Locke SC; Cella DF; Abernethy AP
    Support Care Cancer; 2015 Aug; 23(8):2341-7. PubMed ID: 25586527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of low skeletal muscle mass on non-lung cancer mortality after stereotactic body radiotherapy for patients with stage I non-small cell lung cancer.
    Matsuo Y; Mitsuyoshi T; Shintani T; Iizuka Y; Mizowaki T
    J Geriatr Oncol; 2018 Nov; 9(6):589-593. PubMed ID: 29779799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report.
    Cortellini A; Verna L; Porzio G; Bozzetti F; Palumbo P; Masciocchi C; Cannita K; Parisi A; Brocco D; Tinari N; Ficorella C
    Thorac Cancer; 2019 Feb; 10(2):347-351. PubMed ID: 30600905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consequences of Late-Stage Non-Small-Cell Lung Cancer Cachexia on Muscle Metabolic Processes.
    Murton AJ; Maddocks M; Stephens FB; Marimuthu K; England R; Wilcock A
    Clin Lung Cancer; 2017 Jan; 18(1):e1-e11. PubMed ID: 27461772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer.
    Shoji F; Matsubara T; Kozuma Y; Haratake N; Akamine T; Takamori S; Katsura M; Toyokawa G; Okamoto T; Maehara Y
    Anticancer Res; 2017 Dec; 37(12):6997-7003. PubMed ID: 29187486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of sarcopenia and observed physical performance with attainment of multidisciplinary team planned treatment in non-small cell lung cancer: an observational study protocol.
    Collins JT; Noble S; Chester J; Davies HE; Evans WD; Lester J; Parry D; Pettit RJ; Byrne A
    BMC Cancer; 2015 Jul; 15():544. PubMed ID: 26204885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.